# US 2012/0252849 A1 · Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252849 A1
- Document ID: US20120252849A1
- Status: Published application
- Kind: A1
- Application number: 13/480,108
- Filed: 2012-05-24
- Published: 2012-10-04
- Earliest claimed: 2010-04-29
- Assignees: Deciphera Phamaceuticals, LLC
- Inventors: Daniel L. Flynn; Michael D. Kaufman
- Web page: https://patentgrep.com/patent/US20120252849A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.

## Claims

### Claim 1

A compound of Formula I,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof,
wherein
X is halogen;
Z and Z2 are CR2;
Z3 is CH or N;
each R1 is independently and individually halogen, H, C1-C6 alkyl, branched C3-C7 alkyl, C3-C7 cycloalkyl, or —CN;
each R2 is individually and independently H, halogen, C1-C6 alkyl, or cyano;
R3 is —C(O)R4, —C(O)—C6-C10-aryl, —C(O)—C4-C6-heterocyclyl, or —C(O)—C5-C6-heteroaryl, wherein
aryl is phenyl, naphthyl, tetrahydronaphthyl, indenyl or indanyl; and
with the proviso that when R3 is —C(O)—C4-C6-heterocyclyl, the heterocyclyl does not have a N bonding hand to —C(O);
R4 is C3-C8 cycloalkyl, C1-C7 alkyl, —(CH2)p—CN, —(CH2)p—OR6, —(CH2)p—NR6(R7), —(CH2)p—SO2—C1-C6-alkyl, —(CH2)p—C6-C10-aryl, —(CH2)p—C5-C6-heteroaryl, or —(CH2)p—C4-C6-heterocyclyl, wherein
each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl; and
aryl is phenyl, naphthyl, tetrahydronaphthyl, indenyl or indanyl;
each R6 and R7 is individually and independently H, C1-C6 alkyl, or C3-C8 branched alkyl; each cycloalkyl, aryl, heteroaryl and heterocyclyl is independently substituted with —(R25)m;
each R25 is individually and independently C1-C6 alkyl, branched C3-C8 alkyl, halogen, —(CH2)m—CN, —(CH2)m—OR6, —(CH2)m—NR6(R7), —(CH2)m—SO2—C1-C6-alkyl, —(CH2)m—C(O)NR6(R7), —(CH2)m—C(O)—C4-C6-heterocyclyl, or —(CH2)m—C4-C6-heterocyclyl, wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl;
each m is individually and independently 0, 1, 2, or 3; and
p is 1, 2, or 3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Z3 is CH.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the compound is a compound of Formula Ic,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, and
wherein n is 0, 1, or 2.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R3 is —C(O)R4.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R4 is C3-C8 cycloalkyl, C1-C7 alkyl, —(CH2)p—CN, —(CH2)p—OR6, —(CH2)p—NR6(R7), —(CH2)p—SO2—C1-C6-alkyl, or —(CH2)p—C4-C6-heterocyclyl, and wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl.

### Claim 6 (depends on 4)

The compound of claim 4, wherein R4 is C3-C8 cycloalkyl or C1-C7 alkyl, and wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl.

### Claim 7 (depends on 3)

The compound of claim 3, wherein R3 is —C(O)—C6-C10-aryl, —C(O)—C4-C6-heterocyclyl, or —C(O)—C5-C6-heteroaryl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Z3 is N.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the compound is a compound of Formula If,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, and
wherein
n is 0, 1, or 2.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R3 is —C(O)R4.

### Claim 11 (depends on 9)

The compound of claim 9, wherein R3 is —C(O)—C6-C10-aryl, —C(O)—C4-C6-heterocyclyl, or —C(O)—C5-C6-heteroaryl.

### Claim at position 12

12-19. (canceled)

### Claim 20 (depends on 1)

A compound of claim 1 selected from the group consisting of N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-acetamidopyridin-4-yloxy)-5-chloro-2-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N′-phenylcyclopropane-1,1-dicarboxamide, N-(4-(2-(2-(dimethylamino)acetamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-acetamidopyrimidin-4-yloxy)-2,5-difluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-(2-propionamidopyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-((2-(2-methoxyacetamido)pyridin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-(2-isobutyramidopyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-(2-cyanoacetamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-(azetidine-3-carboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-(cyclobutanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (R)-N-(2,5-difluoro-4-((2-(2-methoxypropanamido)pyridin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (R)-N-(2,5-difluoro-4-((2-(2-hydroxypropanamido)pyridin-4-yl)oxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-((2-pivalamidopyridin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (S)-N-(2,5-difluoro-4-((2-(2-methoxypropanamido)pyridin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (S)-1-((4-(2,5-difluoro-4-(1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxamido)phenoxy)pyridin-2-yl)amino)-1-oxopropan-2-yl acetate, N-(2,5-difluoro-4-((2-(2-fluoro-2-methylpropanamido)pyridin-4-yl)oxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and pharmaceutically acceptable salts and tautomers thereof.

### Claim 21 (depends on 1)

A compound of claim 1 selected from N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-(2-propionamidopyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-(2-isobutyramidopyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.

### Claim 22 (depends on 1)

A method of treating mammalian disease wherein the disease etiology or progression is at least partially mediated by a kinase activity of c-MET, mutant oncogenic forms, aberrant fusion proteins or polymorphs thereof, the method comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 24)

The composition of claim 24, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

### Claim 26 (depends on 1)

A method of treating cancer, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 27 (depends on 26)

The method of claim 26, wherein the compound is administered orally, parenterally, by inhalation, or subcutaneously.

### Claim 28 (depends on 26)

The method of claim 26 wherein the cancer is solid tumors, gastric tumors, esophageal cancer, melanomas, glioblastomas, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, thyroid carcinoma, non-small cell lung cancer, mesothelioma, or colonic cancers.

### Claim 29

The compound N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

A pharmaceutical composition, comprising the compound of claim 29 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 30)

The composition of claim 30, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

### Claim 32

The compound N-(2,5-difluoro-4-(2-propionamidopyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

A pharmaceutical composition, comprising the compound of claim 32 and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 33)

The composition of claim 33, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

### Claim 35

The compound N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, or a pharmaceutically acceptable salt, thereof.

### Claim 36 (depends on 35)

A pharmaceutical composition, comprising the compound of claim 35 and a pharmaceutically acceptable carrier.

### Claim 37 (depends on 36)

The composition of claim 36, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.
